and the drug company shenanigans continue

I realize that I have blogged lots about drug company malfeasance/shenanigans. but they keep on coming and seem to be getting worse. here is another from the NY Times on  Daraprim (the brand name for pyrimethamine, a 62-year old drug used for parasitic infections, most notably for toxoplasmosis in HIV-infected patients but also occasionally for acute malaria) -- see http://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html​ . [thanks to paul susman for bringing this to my attention]. issues:

--Turing pharmaceuticals just acquired the drug and "immediately raised the price to $750 a tablet from $13.50", though several years ago it was $1/pill. of note, "Daraprim's distribution is now tightly controlled, making it harder for generic companies to get the samples they need for the required testing".
--also, cycloserine (used to treat multi-drug resistant TB) was recently acquired by Rodelis Therapeutics, which increased the 30-day supply from $500 to $10,800
--the frequently-used antibiotic doxycycline went from $20/bottle in Oct 2013 to $1849 in April 2014
--and, from NPR's All-Things-Considered (see http://www.npr.org/sections/health-shots/2015/09/10/439219409/naloxone-price-soars-key-weapon-against-heroin-overdoses ), naloxone (Narcan, available since 1971), the main drug used to reverse potentially lethal opioid overdoses, is now a national focus in dealing with the opioid crisis (huge increases in the numbers of people trained to use it, large-scale programs to distribute and make free access to the intranasal form for opioid users, police, etc.) Injectable naloxone had been about $1/shot. The intranasal naloxone is made by only one company (Amphastar). NPR comments that in Baltimore, the price of naloxone in February of $20/dose jumped to $40/dose in July (thanks to sarah taylor for this reference).  
--and, speaking of opioids, though this is more an FDA and drug company joint shenanigans, oxycontin was just approved for kids over 11 years old (see http://www.nytimes.com/aponline/2015/08/13/us/politics/ap-us-oxycontin-children.html​  for the FDA press release and http://www.nytimes.com/2015/09/21/opinion/oxycontin-is-not-for-kids.html?emc=eta1 for an editorial). However, there are several studies finding that children are at a higher risk of addiction than adults (see blogs in http://blogs.bmj.com/ebm/category/pain/  and a USA Today articlehttp://www.usatoday.com/story/news/2015/08/14/fda-approves-oxycontin-kids/31711929/​ ). My feeling on this is that there are some small numbers of kids who need chronic opioids for pain control, that fentanyl patches are already available, and that oxycontin has such a long history of abuse/addiction and is already being abused by kids ("1 in 25 high school seniors has abused oxycontin" per the USA Today report, the number of prescription painkillers has quadrupled since 1999, and >44,000 Americans die of drug overdoses every year). so, seems to me that the risks far outweigh the benefits (except for Purdue Pharmaceuticals, which is undoubtedly laughing all the way to the bank....)

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more